Erratum: Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis (Journal of Cardiovascular Medicine (2014) 15 (873-879) DOI: 10.2459/JCM.0000000000000206);Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis

Journal of Cardiovascular Medicine

Volumn 15, Issue 12, 2014, Pages 873-879

  Fu, Wenbin ^a,b   Guo, Hongyang ^b   Guo, Jianping ^b   Lin, Kun ^b   Wang, Haijun ^b   Zhang, Yu ^a,b   Wang, Yutang ^b   Shan, Zhaoliang ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atrial fibrillation; Network meta analysis; Novel oral anticoagulants; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC DISEASE; ATRIAL FIBRILLATION; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; RISK; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; HEMORRHAGE; HUMANS; ODDS RATIO; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84916942981     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000256     Document Type: Erratum

References (30)

1. Camm AJ, Kirchhof P, Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
2. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14:1385-1413.
3. Colilla S, Crow A, Petkun W., Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol 2013; 112:1142-1147.
4. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
5. Lip GY, Nieuwlaat R, Pisters R., Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137:263-272.
6. Grade A, Grade B, Grade C., Grade D. US cost burden of ischemic stroke: a systematic literature review. Am J Manag Care 2010; 16:525-533.
7. Currie CJ, McEwan P, Emmas C., Morgan CL, Peters JR. Anticoagulation in patients with nonvalvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Curr Med Res Opin 2005; 21:1905-1913.
8. Ansell J, Caro JJ, Salas M, et al Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. Am J Med Qual 2007; 22:327-333.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
10. Granger CB, Alexander JH, McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
11. Patel MR, Mahaffey KW, Garg J, et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
12. Giugliano RP, Ruff CT, Braunwald E, et al Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-2104.
13. Salanti G, Higgins JP, Ades A.E., Ioannidis JP. Evaluation of networks of randomized trials. Stat Meth Med Res 2008; 17:279-301.
14. Liberati A, Altman DG, Tetzlaff J, et al The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-e34.
15. Higgins JP, Altman DG, Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; 343:d5928.
16. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21:2313-2324.
17. Spiegelhalter DJ, Best NG, Carlin B.P., Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002; 64:583-639.
18. Higgins J. Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. 2008.
19. Sturtz S, Ligges U, Gelman AE R2Win BUGS: a package for running Win BUGS from R. J Stat Softw 2005; 12:1-16.
20. Hori M, Matsumoto M, Tanahashi N., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET-AF study. Circulation J 2011; 76:2104-2111.
21. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003; 326:472.
22. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008; 61:455-463.
23. Hohnloser SH. Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma. J Am Coll Cardiol 2011; 57:181-183.
24. Ruff CT, Giugliano RP, Braunwald E, Hoffman E.B., Deenadayalu N., Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955-962.
25. Skjoth F, Larsen TB, Rasmussen L.H., Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: an indirect comparison analysis. Thromb Haemost 2014; 111:981-988.
26. Bucher HC, Guyatt GH, Griffith L.E., Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50:683-691.
27. Dias S, Welton N, Caldwell D., Ades A. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29:932-944.
28. Cameron C, Coyle D, Richter T., et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. Br Med J Open 2014; 2014:2014; 4:e004301.
29. Biondi-Zoccai G., Malavasi V, D'Ascenzo F, et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth 2013; 5:40-54.
30. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: medical. Stat Med 1989; 8:441-454.